By Sabela Ojea

Immunovant said it received positive data from its ongoing 24-week Phase 2 clinical trial for its batoclimab treatment for Graves' disease.

The clinical-stage immunology company on Wednesday said the trial results in patients with Graves' disease meaningfully exceeded 50% response rates.

Batoclimab was generally well tolerated with no new safety signals observed in the initial data set.

Graves' disease is an immune system disorder.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

December 20, 2023 17:25 ET (22:25 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Immunovant (NASDAQ:IMVT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Immunovant Charts.
Immunovant (NASDAQ:IMVT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Immunovant Charts.